ClinicalTrials.gg
Not yet recruitingNCT07476248Updated Mar 17, 2026

The Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus

An observational study in Diabetic Nephropathy and Dyslipidemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
84
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Diabetic Nephropathies by Assiut University — 16 open to participants now, 16 under way, none of them phase 3. Diabetic Nephropathies · Assiut University.

Planned enrollment
13th of 21
84 · median 92
Started
2026
with 4 others
Observational
21 of 25
14 open now
Primary completion
2027-10
later than 12 of 15 live
Registered
21st of 25
by date

Among the 25 studies in Diabetic Nephropathies by Assiut University, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2026, is one of 21 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 21st registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

16 of the 25 studies in Diabetic Nephropathies by Assiut University are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Diabetic Nephropathies by Assiut University, or all of them as a file.
02

Study summary

The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.

Read the detailed description

The study will include adult participants recruited from outpatient clinics and inpatient departments. Participants will be classified into the following groups:

  1. Diabetes Mellitus without Diabetic Nephropathy (DM group) :

    Patients with diabetes mellitus who have no evidence of diabetic nephropathy will be defined by a normal urinary albumin-to-creatinine ratio (UACR) and preserved renal function.

  2. Diabetic Nephropathy group (DN group) :

Patients with diabetes mellitus and diabetic nephropathy will be defined by the presence of elevated UACR and/or impaired renal function as assessed by estimated glomerular filtration rate (eGFR).

Subgroup Analysis :

Within the diabetic nephropathy group, further subgroup analyses will be performed to assess differences in NHHR according to:

Type of diabetes (Type 1 vs. Type 2 diabetes mellitus) Stages of chronic kidney disease (CKD) are classified based on KDIGO definitions of CKD based on estimated GFR and albuminuria.

Type of the study: Comparative cross-sectional study

03

Conditions studied

  • Diabetic Nephropathy
  • Dyslipidemia

Keywords

  • Chronic kidney disease ( CKD )
  • Diabetes mellitus type 1
  • Diabetes mellitus type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with DM attending the internal medicine outpatient clinics and inpatient department.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years
  • Diagnosed cases of diabetes mellitus (Type 1 or Type 2), with or without diabetic nephropathy
  • Willingness to participate and provide

Exclusion criteria

Exclusion Criteria:

  • Known non-diabetic causes of chronic kidney disease
  • Acute kidney injury
  • Chronic inflammatory or diseases
  • Current use of medications known to significantly alter lipid metabolism (other than standard lipid-lowering therapy, if applicable)
  • End-stage renal disease patients on dialysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
84 participants (estimated)
Patient registry
No

Groups and cohorts

  • Diabetes Mellitus without Diabetic Nephropathy (DM group)

    Patients with diabetes mellitus who have no evidence of diabetic nephropathy will be defined by a normal urinary albumin-to-creatinine ratio (UACR) and preserved renal function.

  • Diabetic Nephropathy group (DN group)

    Patients with diabetes mellitus and diabetic nephropathy will be defined by the presence of elevated UACR and/or impaired renal function as assessed by estimated glomerular filtration rate (eGFR). And within the diabetic nephropathy group, further subgroup analyses will be performed to assess differences in NHHR according to: 1. Type of diabetes (Type 1 vs. Type 2 diabetes mellitus) 2. Stages of chronic kidney disease (CKD) are classified based on KDIGO definitions of CKD based on estimated GFR and albuminuria.

06

What researchers measure

Primary outcomes

  1. Association between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and the presence of diabetic nephropathy.

    Diabetic nephropathy defined as urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g and/or estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², measured at enrollment. The non-HDL cholesterol to HDL cholesterol ratio (NHHR) will be calculated from fasting lipid profile obtained at the same visit.

    Time frame: At baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Zhang L, Fan D, Zhu T, Geng L, Gan L, Ou S, Yin D. The ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol is associated with diabetic kidney disease: A cross-sectional study. PLoS One. 2024 Nov 27;19(11):e0311620. doi: 10.1371/journal.pone.0311620. eCollection 2024. PubMed 39602386 ↗
  • Tan MY, Weng L, Yang ZH, Zhu SX, Wu S, Su JH. The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio with type 2 diabetes mellitus: recent findings from NHANES 2007-2018. Lipids Health Dis. 2024 May 21;23(1):151. doi: 10.1186/s12944-024-02143-8. PubMed 38773578 ↗
  • Su X, Rao H, Zhao C, Wu J, Zhang X, Li D. Association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality among hypertension patients. Sci Rep. 2025 Feb 19;15(1):6012. doi: 10.1038/s41598-025-88539-7. PubMed 39972003 ↗
  • Pan X, Lin X, Huang X, Xu J, Ye L, Zhang T, Hu S, Jiang H, Ren Y, Shan PF. The Burden of Diabetes-Related Chronic Kidney Disease in China From 1990 to 2019. Front Endocrinol (Lausanne). 2022 Jun 15;13:892860. doi: 10.3389/fendo.2022.892860. eCollection 2022. PubMed 35784566 ↗
  • Lokpo SY, Laryea R, Osei-Yeboah J, Owiredu WKBA, Ephraim RKD, Adejumo EN, Ametepe S, Appiah M, Peter N, Affrim P, Kwadzokpui PK, Abeka OK. The pattern of dyslipidaemia and factors associated with elevated levels of non-HDL-cholesterol among patients with type 2 diabetes mellitus in the Ho municipality: A cross sectional study. Heliyon. 2022 Aug 17;8(8):e10279. doi: 10.1016/j.heliyon.2022.e10279. eCollection 2022 Aug. PubMed 36046539 ↗
  • Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, Alras Z, Desai SR, Patel KJ, Hooda A, Wehbe M, Sperling LS, Sun YV, Quyyumi AA. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. JAMA Cardiol. 2022 Jul 1;7(7):672-680. doi: 10.1001/jamacardio.2022.0912. PubMed 35583863 ↗
  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. PubMed 19414839 ↗
  • ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Supple 1):S10-S18. doi: 10.2337/dc23-S001. PubMed 36507639 ↗
  • Chen X, Liang M, Zhang J, Xu C, Chen L, Hu R, Zhong J. The Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) to HDL-C Ratio (NHHR) and Its Association with Chronic Kidney Disease in Chinese Adults with Type 2 Diabetes: A Preliminary Study. Nutrients. 2025 Mar 24;17(7):1125. doi: 10.3390/nu17071125. PubMed 40218883 ↗
  • Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet. 2021 Dec 19;396(10267):2019-2082. doi: 10.1016/S0140-6736(20)32374-6. Epub 2020 Nov 12. No abstract available. PubMed 33189186 ↗
  • Achila OO, Fessahye N, Mengistu ST, Habtemikael NT, Werke WY, Zemichael FT, Leghese HN, Weldegegish TA, Tekeste TH, Garoy EY. A community based cross sectional study on the prevalence of dyslipidemias and 10 years cardiovascular risk scores in adults in Asmara, Eritrea. Sci Rep. 2022 Apr 2;12(1):5567. doi: 10.1038/s41598-022-09446-9. PubMed 35368036 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07476248
Lead sponsor
Assiut University
Responsible party
Ragaey Edward Riad (Resident physician, Assiut University) — Principal investigator
First posted
Mar 17, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Mar 17, 2026

Study contacts

Ragaey Edward Riad
Contact
ragaeyedward@gmail.com
+20 1206503994
Ahmed Mohamed Ashmawy, Professor
principal investigator · Assiut University
Noha Gamal Abdel-Malek, Assistant lecturer
principal investigator · Assiut University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion